First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study
J. Clin. Oncol 2024 May 09;[EPub Ahead of Print], S Hegewisch-Becker, G Mendez, J Chao, R Nemecek, K Feeney, E Van Cutsem, SE Al-Batran, W Mansoor, N Maisey, R Pazo Cid, M Burge, D Perez-Callejo, RW Hipkin, S Mukherjee, M Lei, H Tang, S Suryawanshi, RJ Kelly, NC TebbuttFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.